Definition: "An ergogenic aid is any substance or phenomenon that enhances performance "
|
|
||||||||
03.03.2019 |
|
New follistatin analogue makes muscles 19 percent larger in a week
Danish researchers have developed a drug that deactivates the muscle growth inhibiting protein myostatin, but does not have the side effect that hangs like a dark shadow over current myostatin research. When the Danes gave lab animals a modified verrsion of follistatin for a week, their muscle mass increased by as much as 19 percent.
Follistatin
Study
Results
Administering regular follistatin is not efficient. The substance [FST315] disappears from the bloodstream at lightning speed. However, after injections with the modified follistatin molecule [FST-dHBS-hFc] the level of the substance reached impressive levels. In addition, one week after an injection with a large dose the modified molecule [FST-dHBS-mFc] was still detectable in mice's blood.
When the researchers treated mice with the modified follistatin molecule for a week, their body weight increased by 11 percent; the weight of their gastrocnemius increased by 19 percent. The new molecule had a greater anabolic effect than ActRIIA-mFC. [ActRIIA = activin type IIA receptor]
During this week, the Danes injected the mice 3 times with the modified follistatin molecule in their small intestine. This suggests that this molecule may even be active orally. The dose was 10 milligrams per kilogram of body weight. Here you can read how to calculate the human equivalent of that dose.
Unlike ActRIIA-mFC, the new follistatin analogue had no effect on the red blood cells and the blood's viscousness.
Conclusion
"This opens up the possibility of activin receptor signaling pathway therapy in patients with normal or high hematocrit, and it places FST-DHBS-mFc in a unique position among other candidate drugs that interfere with the pathways of the 3 pivotal ligands: activin A, myostatin, and GDF11."
Source:
More: Archives:
|
|